Tilray and Budweiser maker will partner to research weed drinks; Tilray stock jumps

Marijuana producer Tilray Inc. announced Wednesday that it has signed a research partnership with Budweiser maker Anheuser-Busch InBev SA, as the Canadian cannabis industry continues to strike deals with legacy industries.

The joint venture will run through Anheuser-Busch’s BUD, -1.47% subsidiary Labatt Breweries of Canada, and each company intends to invest up to $50 million to research beverages infused with tetrahydrocannabinol, or THC, and cannabidiol, or CBD. THC is the compound that produces psychoactive effects, whereas CBD does not — though it has other properties some see as beneficial.

Tilray TLRY, +0.23%  said that the partnership is limited to Canada, and that the two companies will make decisions about developing products from the research in the future.

“For us, it’s early days in this industry and research feels like the right place to start,” Tilray Chief Executive Brendan Kennedy said in a telephone interview Wednesday morning. “At Tilray, we’ve been performing research and develop for almost five years on lots of different aspects of cannabis and cannabinoid delivery.”

About

Strains

Indica

Sativa

Hybrids

DR.STRAINS(F)2.png

© 2020 Dr. Strains Co.® All Rights Reserved